Open AccessDAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis
Author(s) -
Gallen TrianaBaltzer,
Maria Babizki,
Mcw Chan,
Adam Chun-Nin Wong,
Laura Aschenbrenner,
E. R. Campbell,
QiXiang Li,
Renee W. Y. Chan,
Malik Peiris,
John Nicholls,
Fang Fang
Publication year - 2009
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkp421
Subject(s) - in vivo , respiratory tract , biology , microbiology and biotechnology , in vitro , virology , influenza a virus , respiratory epithelium , virus , ex vivo , sialidase , epithelium , cell culture , immunology , pharmacodynamics , respiratory tract infections , respiratory system , neuraminidase , pharmacology , pharmacokinetics , biochemistry , genetics , anatomy
The influenza virus (IFV) infection models commonly used to evaluate antiviral agents (e.g. MDCK cell line and mice) are limited by physiological differences from the human respiratory tract in vivo. Here we report the pharmacodynamics of DAS181, a sialidase fusion protein that inhibits influenza infection, in the model systems of well-defined human airway epithelium (HAE) culture and ex vivo culture of fresh human bronchial tissue, both of which are close mimics of the human respiratory tract in vivo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom